These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 8826551)

  • 1. Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism.
    Soto J; Sacristan JA; Alsar MJ
    Ann Pharmacother; 1996; 30(7-8):736-9. PubMed ID: 8826551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the time course of drugs with inhibitory effects on hepatic metabolic activity using successive salivary caffeine tests.
    Soto J; Alsar MJ; Sacristan JA
    Pharmacotherapy; 1995; 15(6):781-4. PubMed ID: 8602388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of rifampin treatment on caffeine clearance in healthy man.
    Wietholtz H; Zysset T; Marschall HU; Generet K; Matern S
    J Hepatol; 1995 Jan; 22(1):78-81. PubMed ID: 7751591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects.
    Soto J; Alsar MJ
    J Clin Pharm Ther; 1997 Jun; 22(3):191-5. PubMed ID: 9447474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
    Fromm MF; Busse D; Kroemer HK; Eichelbaum M
    Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients.
    Tarantino G; Conca P; Capone D; Gentile A; Polichetti G; Basile V
    Eur J Clin Pharmacol; 2006 Aug; 62(8):605-12. PubMed ID: 16841221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis].
    Perlík F; Pucelíková T; Slanar O
    Cas Lek Cesk; 2001 Feb; 140(2):51-3. PubMed ID: 11262908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis.
    Bianchetti MG; Kraemer R; Passweg J; Jost J; Preisig R
    J Pediatr Gastroenterol Nutr; 1988; 7(5):688-93. PubMed ID: 3183872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary caffeine clearance predicts survival in patients with liver cirrhosis.
    Jover R; Carnicer F; Sánchez-Payá J; Climent E; Sirvent M; Marco JL
    Am J Gastroenterol; 1997 Oct; 92(10):1905-8. PubMed ID: 9382063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.
    Zheng HX; Huang Y; Frassetto LA; Benet LZ
    Clin Pharmacol Ther; 2009 Jan; 85(1):78-85. PubMed ID: 18843263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study.
    CARE Study Group
    BMJ; 2008 Nov; 337():a2332. PubMed ID: 18981029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intra-individual comparison of the long term effect of Non-Ovlon on caffeine pharmacokinetics].
    Meyer FP; Canzler E; Giers H; Walther H
    Zentralbl Gynakol; 1988; 110(22):1449-54. PubMed ID: 2464882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers.
    Williamson KM; Patterson JH; McQueen RH; Adams KF; Pieper JA
    Clin Pharmacol Ther; 1998 Mar; 63(3):316-23. PubMed ID: 9542475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo modulation of CYP enzymes by quinidine and rifampin.
    Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
    Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
    Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-week treatment with omeprazole increases the metabolism of caffeine.
    Nousbaum JB; Berthou F; Carlhant D; Riche C; Robaszkiewicz M; Gouerou H
    Am J Gastroenterol; 1994 Mar; 89(3):371-5. PubMed ID: 8122647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
    Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
    Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clofibrate and enzymatic induction in man.
    Houin G; Tillement JP
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):150-4. PubMed ID: 649234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.